CClinicalTrials.gg
Not yet recruitingNCT07840872HypershellUpdated Sep 25, 2026

Exploring the Effect of the Hypershell Hip Exoskeleton on Fatiguing, Everyday Activities in Older Adults

An interventional study of Performance test and Hypershell assistance (EXO-ON Actuation) in Fatigue, Older Adults (65 Years and Older) and Exoskeleton Device, sponsored by Vrije Universiteit Brussel. Not yet recruiting at 1 site in Belgium. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Vrije Universiteit Brussel · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn how wearing the Hypershell lower-limb exoskeleton affects perceived fatigue during everyday mobility activities in adults aged 65 years and older. The main questions it aims to answer are:

  • Does active assistance from the Hypershell reduce the development of perceived fatigue during repeated everyday mobility tasks?
  • Does wearing the Hypershell affect how long participants can perform the protocol and how many tasks they can complete before reaching a high level of fatigue?
  • How do participants perceive the usability, comfort, and overall experience of using the Hypershell?
  • What are the biomechanical and physiological responses from wearing the Hypershell?

Researchers will compare two conditions: performing the mobility protocol without the Hypershell and wearing the Hypershell with active assistance.

Participants will:

  • Attend one baseline session including questionnaires, physical tests, and familiarization with the Hypershell and study procedures.
  • Attend two experimental sessions in a randomized order, with at least one week between sessions.
  • Complete a laboratory-based mobility protocol including daily activities such as standing up from a chair, walking, stair climbing, slope walking, walking on uneven surfaces, carrying an object, and performing a cognitive task while walking.
  • Report their perceived fatigue throughout the protocol using the Borg CR10 scale.
  • Wear non-invasive sensors that measure physiological responses and movement during the experimental sessions.
  • Provide feedback about their experience using the HyperShell.
02

Conditions studied

  • Fatigue
  • Older Adults (65 Years and Older)
  • Exoskeleton Device

Browse trials for

03

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Aged 65 years or older
  • Good mobility according to the International Classification of Functioning, Disability and Health (ICF) mobility classification

Exclusion criteria

Exclusion Criteria:

  • Physical injury or disorder that does not allow good physical performance
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    EXO-OFF → EXO-ON Actuation

    Participants complete the FATIG'AGE protocol under two conditions in the following order: without wearing the Hypershell and wearing the Hypershell with active assistance. Experimental sessions are separated by a washout period of at least one week.

    Other: Performance test · Device: Hypershell assistance (EXO-ON Actuation)

  • Experimental
    EXO-ON Actuation → EXO-OFF

    Participants complete the FATIG'AGE protocol under two conditions in the following order: wearing the Hypershell with active assistance and without wearing the Hypershell. Experimental sessions are separated by a washout period of at least one week.

    Other: Performance test · Device: Hypershell assistance (EXO-ON Actuation)

Interventions

  • OtherPerformance test

    Participants will perform the FATIG'AGE multi-task functional mobility protocol. The protocol includes a fixed sequence of daily activities such as walking, sit-to-stand transitions, stair ascent and descent, slope walking, walking on uneven surfaces, carrying an object, and dual-task walking.

    Also known as: FATIG'AGE protocol

  • DeviceHypershell assistance (EXO-ON Actuation)

    Participants wear the Hypershell hip exoskeleton with active assistance. In the active-assistance condition, the device uses motion sensors to detect the user's movements and provides powered assistance to support hip movement during functional mobility tasks

05

What researchers measure

Primary outcomes

  1. Rate of Perceived Fatigue Progression

    Rating of Perceived Fatigue (RPF) will be assessed verbally using the Borg Category-Ratio 10 (CR10) scale after each task of the FATIG'AGE protocol. The Borg CR10 ranges from 0 (no exertion) to 10 (maximal exertion). The rate of increase in RPE across consecutive task executions will be determined for each experimental condition, with a lower rate indicating a slower development of perceived exertion.

    Time frame: During each experimental session, up to 60 minutes

  2. Protocol Duration Until Termination

    Total time, in minutes, that the participant performs the FATIG'AGE protocol before reaching a predefined termination criterion: Borg CR10 greater or equal to two consecutive score of 8, or the maximum protocol duration of 60 minutes. Longer duration indicates that the participant was able to perform the protocol for longer before termination.

    Time frame: During each experimental session, up to 60 minutes

  3. Number of Executed Tasks Until Protocol Termination

    Total number of individual FATIG'AGE task executions completed before reaching a predefined termination criterion: Borg CR10 equal or greater to two consecutive scores of 8, or the maximum protocol duration of 60 minutes. A higher number indicates that more functional mobility tasks were completed before protocol termination.

    Time frame: During each experimental session, up to 60 minutes

Secondary outcomes

  1. Global Perceived Effect of the Hypershell

    Participants will rate the perceived effect of wearing the HyperShell on their physical performance using the Global Perceived Effect (GPE) scale. The GPE is a 7-point Likert scale ranging from perceived deterioration to perceived improvement. The questionnaire will be administered following the HyperShell transparent and active-assistance conditions.

    Time frame: Immediately after each applicable experimental session

  2. Usability of the HyperShell Assessed With the System Usability Scale

    Usability of the Hypershell will be assessed using the 10-item System Usability Scale (SUS). Items are rated on a 5-point Likert scale and transformed into a total score ranging from 0 to 100, with higher scores indicating greater perceived usability.

    Time frame: Immediately after the Hypershell active-assistance experimental session

  3. User Experience With the Hypershell Assessed With the User Experience Questionnaire

    User experience with the Hypershell will be assessed using the 26-item User Experience Questionnaire (UEQ). The questionnaire assesses six dimensions: attractiveness, perspicuity, efficiency, dependability, stimulation, and novelty. Items are scored on a semantic differential scale ranging from -3 to +3, with higher scores indicating a more positive user experience.

    Time frame: Immediately after the Hypershell active-assistance experimental session

  4. Lower-Limb Muscle Activity

    Surface electromyography will be continuously recorded from selected lower-limb muscles (knee extensor, foot dorsi- and plantar flexor) during the FATIG'AGE protocol. Muscle activation amplitude and frequency will be derived from the EMG signal and compared between experimental conditions. Unit of Measure: percent of reference contraction (%)

    Time frame: Continuously during each experimental session, up to 60 minutes

  5. Heart Rate

    Heart rate will be continuously recorded during the FATIG'AGE protocol using electrocardiography. Heart rate will be examined across the protocol and between experimental conditions. Unit of Measure: beats per minute (bpm)

    Time frame: Continuously during each experimental session, up to 60 minutes.

  6. Respiratory Rate

    Respiratory rate will be continuously recorded using an inductive plethysmography band during the FATIG'AGE protocol and examined across the protocol and between experimental conditions. Unit of Measure: breaths per minute

    Time frame: Continuously during each experimental session, up to 60 minutes.

  7. Galvanic Skin Response

    Galvanic skin response will be continuously recorded using finger electrodes during the FATIG'AGE protocol and examined across the protocol and between experimental conditions. Unit of Measure: microsiemens (µS).

    Time frame: Continuously during each experimental session, up to 60 minutes.

  8. Lower-Limb Muscle Oxygen Saturation

    Muscle oxygen saturation will be continuously recorded from selected lower-limb muscles (knee extensor, foot dorsi- and plantar flexor) using near-infrared spectroscopy sensors during the FATIG'AGE protocol and examined across the protocol and between experimental conditions. Unit of Measure: percent (%)

    Time frame: Continuously during each experimental session, up to 60 minutes.

  9. Changes in Motion Data

    Inertial Measurement Unit (IMU) data will be collected continuously throughout the FATIG'AGE protocol. The IMUs will record motion-related signals, including segment orientation, linear acceleration, and angular velocity. Data acquisition will explore changes in kinematics and gait parameters.

    Time frame: Continuously during each experimental session, up to 60 minutes.

06

Study locations

1 site
  • Brubotics Rehabilitation Research Center
    Brussels, 1090, Belgium
07

References and documents

Individual participant data

Plan to share: No — There is currently no plan to make individual participant data (IPD) available to researchers outside the study team. Study data will be securely retained for planned in-house follow-up analyses and to protect participant privacy and confidentiality in accordance with applicable data protection requirements. Aggregate study results will be disseminated through scientific publications and presentations.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07840872
Lead sponsor
Vrije Universiteit Brussel
Responsible party
Eva Swinnen (Professor, Vrije Universiteit Brussel) — Principal investigator
First posted
Sep 25, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Reinhard Claeys
Contact
reinhard.claeys@vub.be
02 477 44 89
Eva Swinnen
Contact
eva.swinnen@vub.be
Eva Swinnen, Prof
principal investigator · Vrije Universiteit Brussel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion